Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752046 | 0.83 | L3MBTL1 (0.45) | LTA4HHTTL3MBTL1LMNA | |
| SCHEMBL6752042 | 0.83 | L3MBTL1 (0.45) | LTA4HHTTL3MBTL1LMNA | |
| SCHEMBL9178257 | 0.78 | TSHR (0.47) | L3MBTL1LMNA | |
| SCHEMBL10775522 | 0.75 | LMNA (0.49) | LTA4HCYP1A2CYP2C19L3MBTL1LMNA | |
| SCHEMBL8639309 | 0.75 | LTA4H (0.47) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Isopropyl Alcohol SCHEMBL10391077 | 0.74 | LMNA (0.47) | LTA4HCYP2D6L3MBTL1LMNAHRH1 | |
| SCHEMBL2130214 | 0.74 | LTA4H (0.48) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10062561 | 0.74 | LTA4H (0.63) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18948936 | 0.73 | ACHE (0.44) | HTTL3MBTL1LMNA | |
| SCHEMBL570480 | 0.73 | LTA4H (1.00) | LTA4HHTTCALM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743784-B2 | TRIARYLETHANES FOR TREATING SYMPTOMS, DISEASES AND CONDITIONS IN EXTRA-REPRODUCTIVE TRACT TISSUES, SUCH AS OSTEOPENIA, THAT ARE RESPONSIVE TO TREATMENT WITH ESTROGEN | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2004-06-01 | — | — | US | disclosed |
| US-20020045664-A1 | Estrogen mimetics lacking reproductive tract effects | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | 2002-04-18 | — | — | US | disclosed |
| US-6323190-B1 | REPRODUCTIVE TRACT TISSUES AND CARDIOVASCULAR DISORDERS | THE UNIVERISTY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045664-A1 | Estrogen mimetics lacking reproductive tract effects | ESR2, ESRRA, GPER1 | LTA4H 3210/4885CYP1A2 282/4885CYP2D6 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.